A LLERGIC RHINITIS, INTERMITtent or persistent, is caused by the deposition of allergens on the nasal mucosa, a process that is followed by a hypersensitivity reaction (type I allergy 1 ). The intermittent and persistent types differ in terms of duration of illness and causative allergens: in most parts of the world, the most common allergens for intermittent allergic rhinitis are grass, tree, and weed pollens, while the most common allergens for persistent allergic rhinitis are house dust mites and domestic animals. The condition is characterized by sneezing, rhinorrhea, obstruction of the nasal passages, lacrimation, and nasal, conjunctival, and pharyngeal itching. 2 Butterbur is an Asteraceae herbaceous plant native to Europe, northern Africa, and southwestern Asia. 3 The leaves and roots of butterbur contain a mixture of eremophilane-type sesquiterpenes (petasins) as pharmacologically active compounds. Two chemovarieties are reported, namely, petasin and furanopetasin chemovarieties, both of which can be distinguished by chemical analysis. The Ze339 extract derives solely from the leaves of the petasin chemovariety. Extracts from roots with a mixture of both chemovarieties have been used in bronchial asthma, smooth muscle spasms, and headache, 4 and studies [5] [6] [7] have shown that petasins inhibit the biosynthesis of leukotrienes, which may be associated with spasmolytic activity and the therapeutic action in type I hypersensitivity.
Butterbur Ze339 is a special extract obtained from the leaves of the butterbur plant (Petasites hybridus, butter dock, bog rhubarb, and exwort). The leaves are cut into small pieces less than 125 µm in length, followed by extraction with liquid carbon dioxide. Compared with extraction with conventional solvents, this method has many advantages. Carbon dioxide prevents oxidation, can be used several times, and is not retained within the extract. Its major advantage is to minimize the extraction of hepatotoxic pyrrolizidine alkaloids. Remaining pyrrolizidine alkaloids are eliminated in one step during the extraction by using the thin-layer alkaloid-absorption method.
The effects of Butterbur Ze339 on seasonal allergic rhinitis have been shown to be significant under methodologically controlled study conditions. 8 In that evaluation of butterbur, we found the treatment advantageous relative to a commonly used antihistamine (cetirizine hydrochloride). Symptomatic treatments such as antihistamines are effective in reducing rhinorrhea and sneezing but are less effective for nasal congestion. Most antihistamines can be obtained over the counter in pharmacies for the symptomatic treatment of allergic rhinitis, although some of them may cause drowsiness, interact with alcohol, and decrease ability to drive or operate machines. 9 Our aim in the present study was to evaluate whether the effects of Butterbur Ze339 extract tablets are dosedependent when tested in a prospectively planned, randomized, placebo-controlled trial and conducted in a sufficiently large number of patients to yield meaningful results.
METHODS

PROTOCOL AND BLINDING
All subjects were outpatients attending 6 general medicine and allergy clinics in Switzerland and Germany between April 4, 2001 , and March 26, 2002. All physicians were experienced in using the instruments of assessment and underwent prestudy training on the scales (Clinical Global Impression and visual analog scale instructions to patients) to enhance intercenter and intracenter consistency. In each clinic, all assessments were made by the same individual.
Study medication consisted of Butterbur (Petasites leaves carbon dioxide extract Ze339, 10 standardized to 8.0 mg of total petasin per tablet), administered at a high-dose (HD) rate of 1 tablet 3 times daily, at a low-dose (LD) rate of 1 tablet twice daily, or as placebo (1 tablet 3 times daily). The LD group received a placebo tablet at the midday dosing to maintain study blindness, so all patients received 3 tablets daily. Blinding was ensured by blister packing with preassigned printed weekly calendar cartons marked as "early morning," "middle of day," and "late evening" doses for all tablets, which were identical in size, color, and smell and were to be taken with a little liquid at the assigned times.
The study was performed according to current International Conference on Harmonization and European Union guidelines on Good Clinical Practice and the Declaration of Helsinki on Human Rights. The study was approved by each clinic's local ethics committee, in Switzerland and Germany.
PATIENT SELECTION
All patients were 18 years or older, had a history of intermittent allergic rhinitis for at least 2 seasons in consecutive years, and fulfilled intermittent allergic rhinitis diagnostic criteria for enrollment ( Table 1 ) required for trials regarding this condition. 11 Exclusions from enrollment included alcohol or substance abuse, pregnant or nursing mothers, parasitic disease causing an increase in IgE or eosinophil levels, use of corticosteroids (systemic or nasal) in the previous 2 months, use of antihistamines in the previous 6 weeks, use of anti-inflammatory agents in the previous 2 weeks, persistent (nonintermittent) rhinitis, prior organ transplantation and serious concomitant disease, or concomitant use of ␣-or ␤-blockers, sympathomimetics, cromoglycates, azelastine hydrochloride, levocabastine hydrochloride, and antidepressants.
Baseline assessment was made at the referral consultation (screening), when the inclusion and exclusion criteria were checked. All patients underwent skin allergy tests, and all were allergic to pollen. Among them, 3 patients were allergic to birch (Betula and Prunus) pollen, 1 patient was allergic to mugwort (Artemisia) pollen, and all others were allergic to grass pollen. Because of the acute nature of the illness and as per guidelines, 11 the initial screening phase was kept short, typically 1 day before starting treatment. At baseline, patients also underwent full medical examination and laboratory tests (hematology, biochemistry, electrocardiogram, and pregnancy test, if female), after which they were given sufficient trial medication for 2 weeks. An intermediate visit after 1 week was optional, in case of adverse events or deterioration. A visit at the end of week 2 (end point) was mandatory, when patients underwent full medical examination, laboratory tests (identical to the screening workup), compliance checks, and adverse events monitoring. Exposure to pollen was confirmed for each patient through cross-checking each individual's treatment period with the regional online pollen count service. 12 Patients' self-assessments were recorded in diaries at 3 preassigned daily times, just before taking medication.
STATISTICS, ASSIGNMENT, AND ANALYSIS
All analyses were prospectively planned, and the data were processed and analyzed by the University of Giessen's Department of Medical Information Technology, Giessen, Germany. Randomization was provided centrally and was computer generated in blocks of 6. Analysis was on an intention-to-treat basis, defined as all randomized patients who had at least the baseline and 1 postbaseline value and took any medication. The planned sample size was a minimum of 60 patients per group, based on previous literature on this condition, 13 with a 10% expected withdrawal rate and an assumed effect size of 0.5. According to current guidelines, 11 the main efficacy variable prospectively sought in the protocol was self-assessment (intraindividual change from baseline to end point, referred to in the guidelines as a reflective score, as an evaluation of overall symptom severity) of the 4 main symptoms (rhinorrhea, nasal congestion, itching, and sneezing) through a visual analog scale in which symptoms were presented in lay terms ("runny nose," "blocked nose," "itchy nose or eyes," and "sneezing"). The scores were subsequently combined for analysis as single global evaluations (sums of 4 main symptom scores). The secondary efficacy variables were (1) Clinical Global Impression 3-item score, 14 (2) a breakdown of the main efficacy variable into an instantaneous score (evaluation of severity immediately before the next dose at predefined times of day) measured daily up to day 7, and (3) an assessment of responder rates, defined as the percentage of patients who achieved 25% improvement or greater in the main efficacy variable.
The working hypothesis was one of superiority for Butterbur Ze339 in a dose-dependent manner at end point, relative to placebo. For the main end point, 2-sided nonparametric statistical tests were performed to detect a difference in the following hierarchical null hypotheses: (1) the expected value of the medians of the intraindividual differences in the total visual analog scale score between the start and end of treatment across the 2 treatment groups, placebo and HD, is identical; (2) the expected value of the medians of the intraindividual differences in the total visual analog scale score between the start and end of treatment across the 2 treatment groups, placebo and LD, is identical; and (3) the expected value of the medians of the intraindividual differences in the total visual analog scale score between the start and end of treatment across the 2 active treatment groups is identical. The hypotheses were tested by the Mann-Whitney test with a probability of type I error of .05 (2-sided). The Shapiro-Wilk test was used to confirm nonnormality of data distribution. In addition, 25th to 75th percentiles for the expected value and the medians, means, and standard deviations were calculated. For withdrawal cases, the last observation carried forward method was applied. Missing values were substituted by the mean of all patients in the 3 treatment groups combined.
The exploratory secondary variables were evaluated, where appropriate, in a manner similar to the main efficacy variable or by inference statistics with a shifted null hypothesis adjustment to baseline according to Abt, 15 with means, standard deviations, medians, 25th to 75th percentiles, minima, maxima, and absolute and relative frequencies. Responder rates were evaluated by 2 test.
RESULTS
PATIENTS' CHARACTERISTICS AND FLOW THROUGH STUDY
Two hundred forty patients were referred for screening, 186 of whom fulfilled the enrollment criteria, consented to be randomized, and received at least 1 dose of study medication (Figure 1 ). All 186 patients were included in the analysis. Patients' characteristics at entry were balanced ( 2 ) across the 3 groups ( Table 2 ). The population was representative of intermittent allergic rhinitis patients who seek treatment in the primary care sector, with almost two thirds of patients being female and one quarter of patients being smokers. All 4 main symptoms of the illness were moderately severe or worse in most patients, (Table 2) , as previously observed. 8 Sneezing, nasal congestion, and itchy eyes or nose had similar frequency and severity across the treatment groups. One patient in each group used antihistamines during the study, but, despite this being a protocol exclusion, all were included in the analysis.
EFFICACY RESULTS
The results at the end of the treatment period are displayed in Tables 3, 4 , and 5. Analysis of the main efficacy variable confirmed that Butterbur Ze339 is dosedependently superior to placebo in relieving the 4 main symptoms of intermittent allergic rhinitis (Tables 3 and  4 and Figure 2 ). Although both doses were individually significantly (PϽ.001) superior to placebo, the HD group was also significantly (P = .02) superior to the LD group.
Analysis of the second efficacy variable, Clinical Global Impression 3-item score (1, severity; 2, global improvement; and 3, risk-benefit), yielded results similar to those of the main variable, with the 2 active groups being significantly superior to placebo in all 3 items. However, differences between the 2 active dose groups were present only in item 2 (global improvement), favorable to the HD group. Regarding the instantaneous symptoms scores (evaluated immediately before the next dosing), the HD group was significantly superior to placebo, but the LD group was only marginally superior to placebo (significantly on day 5), failing to reach significance at day 7. The significant improvements in the HD group were consistently present from day 3 onward. Responder rates were also significantly higher for the 2 active dosing groups relative to placebo.
SAFETY RESULTS
The overall incidence of adverse events and treatment withdrawals was low ( Table 6 ). The most commonly reported event (gastrointestinal upset) was present similarly across †From Bousquet et al. 1 Clinical Global Impression (CGI) Item 1: no examination possible, patient not ill, borderline ill, only slightly ill, moderately ill, clearly ill, severely ill, extremely severely ill. Item 2: no examination possible, very much better, much better, little better, no change, little worse, much worse, very much worse. Item 3: unchanged or worse, little or slight improvement, moderate to clear improvement, very good improvement.
‡Mann-Whitney test (2-sided). The CGI items are handled as "equidistant" to allow testing. Significant values indicate superiority over comparator group. The final P value (for responder rates) was 2 on the percentage of patients with Ն25% improvement in the main variable from baseline to end point.
§Negative values represent improvement in scores.
Positive values represent improvement in scores. active and placebo groups. There was no evidence to suggest an event that could be considered as typically associated with active treatment, with most events being reported once or twice only. Events causing treatment withdrawal also had similar incidence across all groups.
COMMENT
The large number of antihistamines and corticosteroid nasal sprays, available without prescription, and their wide use in the spring and early summer highlight the dimension of the problems caused by intermittent allergic rhinitis in patients, as evidenced by most physicians involved in primary care and by allergy specialists. Yet, methodologically robust studies are difficult to conduct in intermittent allergic rhinitis, in part because of the acute nature of the illness and wide scope of access to antiallergic treatments by patients. Although regulatory guidelines exist on the criteria for selection and evaluation of patients in intermittent allergic rhinitis trials, 11 the inclusion of a placebo group can be problematic, because of possible contamination of results by the use of other treatments readily available to ameliorate unpleasant symptoms such as runny nose, sneezing, itching, and congestion. We monitored our patients closely and allowed them to visit the clinics whenever they thought their condition needed further intervention; hence, our control subjects exhibited the level of treatment failures and interruptions that would be expected in a 2-week treatment, as in our experience patients with intermittent allergic rhinitis do not tolerate ineffective treatments for longer periods. The length of treatment was also chosen according to regulatory guidelines. Treatment compliance was monitored and was identical for all treatment groups. We considered the addition of an active comparator but decided against it as this comparison had already been conducted with a similar design 8 and the addition of a further treatment group would delay completion by another season (year), with a consequent increase in variability of the data. We excluded the use of corticosteroids of any kind (including nasal) 2 months before and during the study. We then formulated the hypothesis of whether this herbal treatment was superior to placebo in a dosedependent manner, prospectively in the protocol, and tested the hypothesis hierarchically so that the analysis would stop if any of the tested items of the patients' self-assessment showed the herbal drug to be similar to placebo. Finally, we confirmed patients' exposure to the allergens through regional pollen counts for each patient's treatment period and by checking each patient's days' exposure indoors and outdoors, all of which were similar across groups, with 98% of allergens being grass pollen.
The use of herbal treatments in the last decade has increased tremendously, often by physicians' recommendation and frequently after requests from patients; consequently, the number of published randomized controlled trials with herbal medicines has increased substantially. 8, [16] [17] [18] Although the effects of butterbur on the preclinical and clinical pathogenesis of allergen hypersensitivity have also increased substantially, [19] [20] [21] we set out to test Butterbur Ze339 in a methodologically robust, controlled design in which a dose relationship of its clinical effects in intermittent allergic rhinitis could be tested against placebo and judged separately and blindly by patients and their physicians. The results showed that both doses of this herbal drug are significantly and increasingly effective relative to dose, similar to traditional synthetic medicines. The clinical benefit can be detected rapidly, usually within a few days' treatment. With regard to safety, Butterbur Ze339 was well tolerated.
We collected data on overall effects throughout the dosing period (also referred to as reflective in the guide- lines), as well as trough effects (also referred to as instantaneous in the guidelines), the latter showing that, although the LD improves overall symptoms, the effects do not last until the next dosing.
CONCLUSIONS
This prospective, randomized, double-blind, placebocontrolled study demonstrated that Butterbur Ze339 extracted from leaves of the petasin chemovariety is effective in treating the symptoms of intermittent allergic rhinitis in a dose-dependent manner. This treatment raised no tolerability concerns regarding adverse events. The effects of this herbal extract were confirmed by patients and physicians who were blinded to treatment codes during the study, in the presence of a control group receiving placebo. Butterbur Ze339 should be considered for treating intermittent allergic rhinitis in patients in whom antihistamines are not indicated or when sedation is to be avoided. Disclaimer: Dr Schapowal is the principal investigator and guarantor of the article. He had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the analysis, which was conducted by Joachim Dudeck, PhD (Department of Medical Information Studies, University of Giessen), who also conducted data audit and management. The analysis was conducted independently by the University of Giessen, and the interpretation of the results was the prerogative of Dr Schapowal and the Petasites Study Group.
